Falcon 9 v1.1

MIPI Alliance Releases A-PHY v1.1, Doubling Maximum Data Rate and Adding New Implementation Options to Automotive SerDes Interface

Retrieved on: 
Tuesday, January 18, 2022
Data Management, Automotive, General Automotive, Technology, Mobile, Wireless, Software, Hardware, ADAS, G1, MASS, IP, Technology, Automotive industry, MIPI, Data-rate units, MIPI Alliance, Falcon 9 v1.1, IEEE, STQ, LinkedIn, Eastern Football Netball League, Adoption, IVI, Écu, PST, Facebook, ADS, Working Group, Education, YouTube, Original equipment manufacturer, SerDes, Twitter, Hertz, Smartphone, Blog, Television, Consumer electronics, Mobile phone, G2

The MIPI Alliance , an international organization that develops interface specifications for mobile and mobile-influenced industries, today announced the release of MIPI A-PHY v1.1, the next version of the automotive serializer-deserializer (SerDes) physical-layer interface.

Key Points: 
  • The MIPI Alliance , an international organization that develops interface specifications for mobile and mobile-influenced industries, today announced the release of MIPI A-PHY v1.1, the next version of the automotive serializer-deserializer (SerDes) physical-layer interface.
  • It also forms the foundation of MIPI's Automotive SerDes Solutions (MASS) , an end-to-end framework for connecting cameras, sensors and displays with built-in functional safety, security and data protection.
  • The MIPI Alliance also hosted a virtual Automotive Workshop in November to provide more in-depth education on its MASS framework.
  • To keep up with MIPI Alliance, subscribe to the MIPI blog and stay connected by following MIPI on Twitter , LinkedIn , Facebook and YouTube .

Deciphera Pharmaceuticals Presents New Clinical Study Results Across Pipeline at the European Society for Medical Oncology (ESMO) Congress 2021

Retrieved on: 
Friday, September 17, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Intracranial hemorrhage, Patient, Â, View, LinkedIn, U.S. Securities and Exchange Commission, Paclitaxel, BID, Progression-free survival, PFS, Program, Duration, Part 1, GIST, Private Securities Litigation Reform Act, RECIST, Șaeș, Survival, Mitt, CSF1R, NASDAQ, Pharmacokinetics, MD, Growth, COVID-19, Webcast, Feedback, Cancer, Falcon 9 v1.1, Trial of the century, Cohort study, ESMO, OS, HIV disease progression rates, Safety, SEC, Part, Maintenance, The Retreat, Company, LLC, Disease, PROC, ORR, KIT, Congress, Pharmaceutical industry, Engineered wood, Medical imaging, Phosphorus

We are equally encouraged by the tolerability and efficacy data presented today from the Phase 1/2 study of vimseltinib in TGCT.

Key Points: 
  • We are equally encouraged by the tolerability and efficacy data presented today from the Phase 1/2 study of vimseltinib in TGCT.
  • The data presented today with vimseltinib in TGCT reinforce its potential to be a best-in-class treatment for this disease.
  • The data presented today is from the second stage of Part 2 of the Simon two-stage design in PROC.
  • QINLOCK and the QINLOCK logo are registered trademarks, and Deciphera and the Deciphera logo are trademarks, of Deciphera Pharmaceuticals, LLC.